The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer.
作者： Srividya Srinivasamaharaj , Bilal Khameze Salame , Jorge Rios-Perez , Goetz Kloecker , Cesar A. Perez
DOI: 10.1080/14737140.2016.1249857
关键词:
摘要: ABSTRACTIntroduction: The identification of anaplastic lymphoma kinase (ALK) gene rearrangements in subsets non-small cell lung cancer patients has provided with unparalleled opportunities to hinder the progression this disease through targeting activity these specific molecules. Unfortunately most develop less than a year treatment crizotinib, first-generation ALK-inhibitor.Areas covered: We review resistance mechanisms ALK inhibitors as well an overview clinical alectinib, second generation inhibitor.Expert commentary: Second alectinib and ceritinib can overcome crizotinib-resistant mutations improve central nervous system control. Novel third-generation combination agents give hope achieving even longer control next decade.
sci-hub.se 参考文章(51)
Yan Xu, Hongyu Liu, Jun Chen, Qinghua Zhou, Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 Thoracic Cancer. ,vol. 1, pp. 83- 86 ,(2010) , 10.1111/J.1759-7714.2010.00016.X
Laird Cameron, Benjamin Solomon, Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions. Drugs. ,vol. 75, pp. 1059- 1070 ,(2015) , 10.1007/S40265-015-0415-9
Annie Guérin, Medha Sasane, Jie Zhang, Alexander R. Macalalad, Philip Galebach, John Jarvis, Andrew Kageleiry, Kenneth Culver, Eric Q. Wu, Heather Wakelee, ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. Cancer Epidemiology. ,vol. 39, pp. 307- 312 ,(2015) , 10.1016/J.CANEP.2015.04.005
Gouji Toyokawa, Takashi Seto, Anaplastic lymphoma kinase rearrangement in lung Cancer: Its biological and clinical significance Respiratory investigation. ,vol. 52, pp. 330- 338 ,(2014) , 10.1016/J.RESINV.2014.06.005
Daniela Iacono, Rita Chiari, Giulio Metro, Chiara Bennati, Guido Bellezza, Matteo Cenci, Biagio Ricciuti, Angelo Sidoni, Sara Baglivo, Vincenzo Minotti, Lucio Crinò, Future options for ALK-positive non-small cell lung cancer Lung Cancer. ,vol. 87, pp. 211- 219 ,(2015) , 10.1016/J.LUNGCAN.2014.12.017
Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J. Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire, Erik Thunnissen, Marc Ladanyi, Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Journal of Thoracic Oncology. ,vol. 8, pp. 823- 859 ,(2013) , 10.1097/JTO.0B013E318290868F
Zilan Song, Meining Wang, Ao Zhang, Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance Acta Pharmaceutica Sinica B. ,vol. 5, pp. 34- 37 ,(2015) , 10.1016/J.APSB.2014.12.007
Young Lim Choi, Manabu Soda, Yoshihiro Yamashita, Toshihide Ueno, Junpei Takashima, Takahiro Nakajima, Yasushi Yatabe, Kengo Takeuchi, Toru Hamada, Hidenori Haruta, Yuichi Ishikawa, Hideki Kimura, Tetsuya Mitsudomi, Yoshiro Tanio, Hiroyuki Mano, EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors The New England Journal of Medicine. ,vol. 363, pp. 1734- 1739 ,(2010) , 10.1056/NEJMOA1007478
Lynette M Sholl, Dara L Aisner, Marileila Varella-Garcia, Lynne D Berry, Dora Dias-Santagata, Ignacio I Wistuba, Heidi Chen, Junya Fujimoto, Kelly Kugler, Wilbur A Franklin, A John Iafrate, Marc Ladanyi, Mark G Kris, Bruce E Johnson, Paul A Bunn, John D Minna, David J Kwiatkowski, LCMC Investigators, None, Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The lung cancer mutation consortium experience Journal of Thoracic Oncology. ,vol. 10, pp. 768- 777 ,(2015) , 10.1097/JTO.0000000000000516
Howard L West, Michele C Azada, Peter N Morcos, Ruey-Min Lee, Linta Garcia, Li Yu, Frederic Boisserie, Laura Di Laurenzio, Sophie Golding, Jotaro Sato, Shumpei Yokoyama, Tomohiro Tanaka, Sai-Hong Ignatius Ou, Shirish M Gadgeel, Leena Gandhi, Gregory J Riely, Alberto A Chiappori, Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study Lancet Oncology. ,vol. 15, pp. 1119- 1128 ,(2014) , 10.1016/S1470-2045(14)70362-6